Pages that link to "Q39652300"

The following pages link to ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase (Q39652300):

Displaying 49 items.

• Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B (Q27030828) (← links)
• Intracellular substrates for the primer-unblocking reaction by human immunodeficiency virus type 1 reverse transcriptase: detection and quantitation in extracts from quiescent- and activated-lymphocyte subpopulations (Q33770095) (← links)
• Recent findings on the mechanisms involved in tenofovir resistance (Q33831709) (← links)
• Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision (Q33836938) (← links)
• Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase (Q34254673) (← links)
• The "Connection" Between HIV Drug Resistance and RNase H (Q34313605) (← links)
• Tenofovir disoproxil fumarate (Q34534058) (← links)
• Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection (Q34551836) (← links)
• Tenofovir disoproxil fumarate for the treatment of HIV infection (Q34569309) (← links)
• The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations (Q34647936) (← links)
• A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors (Q35105821) (← links)
• Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections (Q35558801) (← links)
• The effects of RNase H inhibitors and nevirapine on the susceptibility of HIV-1 to AZT and 3TC (Q35684111) (← links)
• Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy (Q35842525) (← links)
• HIV-1 antiretroviral drug therapy (Q35853012) (← links)
• Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir (Q35912746) (← links)
• Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections (Q35917125) (← links)
• Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistance (Q35917530) (← links)
• Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro (Q36076011) (← links)
• Understanding the molecular mechanism of sequence dependent tenofovir removal by HIV-1 reverse transcriptase: differences in primer binding site versus polypurine tract (Q36098779) (← links)
• Tenofovir resistance and resensitization (Q36879987) (← links)
• Viral drug resistance and fitness. (Q37034618) (← links)
• Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. (Q37083800) (← links)
• Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision (Q37492877) (← links)
• The 3'-azido group is not the primary determinant of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1. (Q38324643) (← links)
• Molecular determinants of multi-nucleoside analogue resistance in HIV-1 reverse transcriptases containing a dipeptide insertion in the fingers subdomain: effect of mutations D67N and T215Y on removal of thymidine nucleotide analogues from blocked DN (Q38343144) (← links)
• Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations (Q38344427) (← links)
• The Y181C substitution in 3'-azido-3'-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer (Q38351813) (← links)
• Therapy of HIV Infection: Current Approaches and Prospects (Q39066550) (← links)
• Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analogue-resistant mutants (Q39077432) (← links)
• Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors. (Q39142877) (← links)
• Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity (Q39657878) (← links)
• Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure (Q39664167) (← links)
• Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation (Q39732544) (← links)
• Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages. (Q40173457) (← links)
• Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its (Q40733425) (← links)
• Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate (Q41856023) (← links)
• Structure and conformational analysis of the anti-HIV reverse transcriptase inhibitor AZT using MP2 and DFT methods. Differences with the natural nucleoside thymidine. Simulation of the 1st phosphorylation step with ATP. (Q42183553) (← links)
• Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility (Q43077557) (← links)
• Tautomerism of the natural thymidine nucleoside and the antiviral analogue D4T. Structure and influence of an aqueous environment using MP2 and DFT methods. (Q43196904) (← links)
• Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses (Q44372189) (← links)
• Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC. (Q44486147) (← links)
• Studies of molecular mechanism of Tenofovir against 3TC- and AZT-resistance mutant HIV-1 reverse transcriptase (Q44638689) (← links)
• Effects of primer-template sequence on ATP-dependent removal of chain-terminating nucleotide analogues by HIV-1 reverse transcriptase (Q45016660) (← links)
• Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. (Q45289817) (← links)
• The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V. (Q46718140) (← links)
• Site-specific footprinting reveals differences in the translocation status of HIV-1 reverse transcriptase. Implications for polymerase translocation and drug resistance (Q47814140) (← links)
• Global view of a drug-sensitivity gene network (Q49850476) (← links)
• Tenofovir disoproxil fumarate (Q73724737) (← links)